Table 4.
Single-targeting, non-anti-BCMA CAR T-cell therapy in patients with RRMM.
| CAR T Product | NCT Reference | Antigen Target | Phase | Patient Population | Primary Outcome |
|---|---|---|---|---|---|
| CAR2 anti-CD38 A2 CAR T Cells | NCT03464916 | CD38 | I | RR/MM (following prior lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab) or RR/MM (within 1 year of high-dosefirst-line or second-line therapy/ASCT) | Determine the MTD |
| MLM-CAR44.1 T-cells | NCT04097301 | CD44v6 | I/II | RR/MM (≥4 different prior treatments in 3 treatment lines, or 4 treatments in 2 treatment lines in early relapsing patients) | MTD and recommended phase IIa dose |
| Not Known | NCT03958656 | SLAMF7 | I | RR/MM ( ≥3 prior regimens) | Safety by frequency of AEs |
| ATLCAR. CD138 cell |
NCT03672318 | CD138 | I | RR/MM (up to 2 treatment lines if refractory to both IMiD and PI) | Proportion of participants with DLTs as a measure of MTD |
AE: adverse event; ASCT: autologous stem cell transplant; CAR: chimeric antigen receptor; DLT: dose-limiting toxicity; IMiD: immunomodulatory agent; MTD: maximum tolerated dose; R/R: relapsed/refractory; PI: proteasome inhibitor.